165 related articles for article (PubMed ID: 24924778)
1. ASC-J9 suppresses renal cell carcinoma progression by targeting an androgen receptor-dependent HIF2α/VEGF signaling pathway.
He D; Li L; Zhu G; Liang L; Guan Z; Chang L; Chen Y; Yeh S; Chang C
Cancer Res; 2014 Aug; 74(16):4420-30. PubMed ID: 24924778
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor (AR) suppresses miRNA-145 to promote renal cell carcinoma (RCC) progression independent of VHL status.
Chen Y; Sun Y; Rao Q; Xu H; Li L; Chang C
Oncotarget; 2015 Oct; 6(31):31203-15. PubMed ID: 26304926
[TBL] [Abstract][Full Text] [Related]
3. ASC-J9
Lin W; Luo J; Sun Y; Lin C; Li G; Niu Y; Chang C
Cancer Lett; 2018 Jul; 425():21-30. PubMed ID: 29425687
[TBL] [Abstract][Full Text] [Related]
4. The effects of RNA interference mediated VEGF gene silencing on biological behavior of renal cell carcinoma and transplanted renal tumor in nude mice.
Wang Q; Wang S; Sun SQ; Cheng ZH; Zhang Y; Chen G; Gu M; Yao HJ; Wang Z; Zhou J; Peng YB; Xu MX; Zhang K; Sun XW
Cancer Biomark; 2016; 16(1):1-9. PubMed ID: 26484606
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor (AR) degradation enhancer ASC-J9
Cheng MA; Chou FJ; Wang K; Yang R; Ding J; Zhang Q; Li G; Yeh S; Xu D; Chang C
Cancer Lett; 2018 Mar; 417():182-191. PubMed ID: 29203251
[TBL] [Abstract][Full Text] [Related]
6. Infiltrating neutrophils promote renal cell carcinoma progression via VEGFa/HIF2α and estrogen receptor β signals.
Song W; Yeh CR; He D; Wang Y; Xie H; Pang ST; Chang LS; Li L; Yeh S
Oncotarget; 2015 Aug; 6(22):19290-304. PubMed ID: 26079540
[TBL] [Abstract][Full Text] [Related]
7. C1QBP Regulates YBX1 to Suppress the Androgen Receptor (AR)-Enhanced RCC Cell Invasion.
Yue D; Wang Y; Sun Y; Niu Y; Chang C
Neoplasia; 2017 Feb; 19(2):135-144. PubMed ID: 28107702
[TBL] [Abstract][Full Text] [Related]
8. Suppression of mitochondrial respiration with auraptene inhibits the progression of renal cell carcinoma: involvement of HIF-1α degradation.
Jang Y; Han J; Kim SJ; Kim J; Lee MJ; Jeong S; Ryu MJ; Seo KS; Choi SY; Shong M; Lim K; Heo JY; Kweon GR
Oncotarget; 2015 Nov; 6(35):38127-38. PubMed ID: 26474388
[TBL] [Abstract][Full Text] [Related]
9. Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as anti-cancer strategies.
Guyot M; Hilmi C; Ambrosetti D; Merlano M; Lo Nigro C; Durivault J; Grépin R; Pagès G
Oncotarget; 2017 Feb; 8(6):9174-9188. PubMed ID: 27999187
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor (AR) signaling promotes RCC progression via increased endothelial cell proliferation and recruitment by modulating AKT → NF-κB → CXCL5 signaling.
Guan Z; Li C; Fan J; He D; Li L
Sci Rep; 2016 Nov; 6():37085. PubMed ID: 27848972
[TBL] [Abstract][Full Text] [Related]
11. ASC-J9® suppresses prostate cancer cell proliferation and invasion via altering the ATF3-PTK2 signaling.
Tian H; Chou FJ; Tian J; Zhang Y; You B; Huang CP; Yeh S; Niu Y; Chang C
J Exp Clin Cancer Res; 2021 Jan; 40(1):3. PubMed ID: 33390173
[TBL] [Abstract][Full Text] [Related]
12. Preclinical study using androgen receptor (AR) degradation enhancer to increase radiotherapy efficacy via targeting radiation-increased AR to better suppress prostate cancer progression.
Chou FJ; Chen Y; Chen D; Niu Y; Li G; Keng P; Yeh S; Chang C
EBioMedicine; 2019 Feb; 40():504-516. PubMed ID: 30692044
[TBL] [Abstract][Full Text] [Related]
13. Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma.
Han KS; Raven PA; Frees S; Gust K; Fazli L; Ettinger S; Hong SJ; Kollmannsberger C; Gleave ME; So AI
Neoplasia; 2015 Nov; 17(11):805-16. PubMed ID: 26678908
[TBL] [Abstract][Full Text] [Related]
14. LncRNA-SARCC suppresses renal cell carcinoma (RCC) progression via altering the androgen receptor(AR)/miRNA-143-3p signals.
Zhai W; Sun Y; Guo C; Hu G; Wang M; Zheng J; Lin W; Huang Q; Li G; Zheng J; Chang C
Cell Death Differ; 2017 Sep; 24(9):1502-1517. PubMed ID: 28644440
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor increases hematogenous metastasis yet decreases lymphatic metastasis of renal cell carcinoma.
Huang Q; Sun Y; Ma X; Gao Y; Li X; Niu Y; Zhang X; Chang C
Nat Commun; 2017 Oct; 8(1):918. PubMed ID: 29030639
[TBL] [Abstract][Full Text] [Related]
16. PHGDH as a Key Enzyme for Serine Biosynthesis in HIF2α-Targeting Therapy for Renal Cell Carcinoma.
Yoshino H; Nohata N; Miyamoto K; Yonemori M; Sakaguchi T; Sugita S; Itesako T; Kofuji S; Nakagawa M; Dahiya R; Enokida H
Cancer Res; 2017 Nov; 77(22):6321-6329. PubMed ID: 28951458
[TBL] [Abstract][Full Text] [Related]
17. Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene.
Liu MY; Poellinger L; Walker CL
Cancer Res; 2003 May; 63(10):2675-80. PubMed ID: 12750296
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.
Bai L; Yang JC; Ok JH; Mack PC; Kung HJ; Evans CP
Int J Cancer; 2012 Jun; 130(11):2693-702. PubMed ID: 21792888
[TBL] [Abstract][Full Text] [Related]
19. ASC-J9® increases the bladder cancer chemotherapy efficacy via altering the androgen receptor (AR) and NF-κB survival signals.
Huang CP; Chen J; Chen CC; Liu G; Zhang Y; Messing E; Yeh S; Chang C
J Exp Clin Cancer Res; 2019 Jun; 38(1):275. PubMed ID: 31234917
[TBL] [Abstract][Full Text] [Related]
20. Targeting newly identified ERβ/TGF-β1/SMAD3 signals with the FDA-approved anti-estrogen Faslodex or an ERβ selective antagonist in renal cell carcinoma.
Song W; He D; Chen Y; Yeh CR; Hsu I; Huang Q; Zhang X; Chang LS; Zuo L; Chen J; Doersch KM; Chang C; Li L; Yeh S
Mol Oncol; 2018 Dec; 12(12):2055-2071. PubMed ID: 30171816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]